A longitudinal examination of the psychoeducational, neurocognitive, and psychiatric functioning in children with 22q11.2 deletion syndrome by Hooper, Stephen et al.
A Longitudinal Examination of the Psychoeducational,
Neurocognitive, and Psychiatric Functioning in Children with
22q11.2 Deletion Syndrome
Stephen R. Hooper, Ph.D.a,b, Kathleen Curtiss, Ph.D.b, Kelly Schoch, M.S.b, Matcheri S.
Keshavan, M.D.c, Andrew Allen, PhD.d, and Vandana Shashi, M.D.b
aDepartment of Psychiatry and The Carolina Institute for Developmental Disabilities, University of
North Carolina School of Medicine, CB# 7255, Chapel Hill, NC, USA, 27599-7255.
bDepartment of Psychiatry, Duke University Medical School, GSRB1 Box 103857, 595 LaSalle
St., Durham, NC, USA, 27710
cDepartment of Psychiatry, Harvard Medical School, Commonwealth Research Center, 75
Fenwood Rd, 5th Floor, Boston, MA, USA, 02115
dDepartment of Biostatistics, Duke University School of Medicine, 7057 North Pavilion, Durham,
NC, USA 27710
Abstract
The present study sought to examine the longitudinal psychoeducational, neurocognitive, and
psychiatric outcomes of children and adolescents with chromosome 22q11.2 deletion syndrome
(22q11DS), a population with a high incidence of major psychiatric illnesses appearing in late
adolescence/early adulthood. Little is known of the developmental changes that occur in the early
teen years, prior to the age of highest psychosis risk. Data were collected from 71 participants (42
subjects with 22q11DS and 29 control subjects) at Time 1 (T1) and Time 2 (T2), approximately
3.5 years later. The 22q11DS group was significantly lower functioning than controls on IQ,
neurocognition, and academic achievement at both T1 and T2. Children with 22q11DS also
showed significantly greater social-behavioral difficulties and psychiatric symptoms, and were
more likely to meet criteria for psychiatric disorders at both time points. In evaluating change over
time from T1 to T2, the 22q11DS group did not show significant changes in psychoeducational or
psychiatric outcomes relative to the controls, however, lack of expected age-related gains in
attention regulation were noted. Within the 22q11DS group, an increase in the Attenuated
Prodrome for Schizophrenia (number of psychiatric symptoms) was noted from T1 to T2 and four
children with 22q11DS met criteria for Psychosis for the first time. Predictors at T1 that
uncovered psychopathology symptoms at T2 included full-scale IQ, externalizing symptoms, and
problem social behaviors. Overall, younger adolescent and preadolescent children with 22q11DS
in this study exhibited slowed growth in attention regulation, with an increase in subclinical
symptoms of schizophrenia, suggestive of increasing impairments in domains that are relevant to
the high risk of Schizophrenia. Early predictors of later psychopathology included both cognitive
and behavioral abnormalities. These findings begin to elucidate the trajectory of changes in
psychopathology in children with 22q11DS in the years leading up to the onset of major
psychiatric illnesses.
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1. Introduction
Chromosome 22q11.2 Deletion Syndrome (22q11DS), also known as Velocardiofacial
syndrome (VCFS) or DiGeorge Syndrome, is the most common microdeletion syndrome in
humans with an incidence of 1:2,000 to 1:4,000 (Devriendt, Fryns, Mortier, van Thienen, &
Keymolen, 1998; Shprintzen, 2000b, 2008; Wilson et al., 1994). In addition to multiple
medical problems, individuals with 22q11DS experience a wide range of neurocognitive
impairments and a high rate of major psychiatric disorders (Robin & Shprintzen, 2005;
Shprintzen, 2000a).
Intellectual functioning in children with 22q11DS varies from the borderline to mild
intellectual disability range, along with deficits in sustained attention, executive function,
and visual spatial functioning, with some reported similarities to a non-verbal learning
disability (De Smedt et al., 2007; Jacobson et al., 2010; Lewandowski, Shashi, Berry, &
Kwapil, 2007; Moss et al., 1999; Schoch et al., 2012; Swillen et al., 1997; Woodin et al.,
2001). Common psychiatric disorders in childhood include Attention-Deficit/Hyperactivity
Disorder (ADHD) and anxiety disorders such as Specific Phobias and Obsessive-
Compulsive Disorder (OCD; Antshel et al., 2007). In particular, children with 22q11DS
evidence a poor repertoire of social skills and high rates of internalizing symptoms (Kiley-
Brabeck & Sobin, 2006; Shashi et al., 2011). In a prior study, we found that about 60% of
children with 22q11DS met criteria for at least one psychiatric diagnosis, with the most
frequent diagnoses including ADHD and various anxiety disorders (Lewandowski et al.,
2007; Young, Shashi, Schoch, Kwapil, & Hooper, 2011). In later adolescence or early
adulthood, upwards of 25% develop major psychiatric illnesses such as Schizophrenia,
Bipolar illness, and Major Depression (Baker & Skuse, 2005; Murphy, Jones, & Owen,
1999; Papolos et al., 1996; Pulver et al., 1994; Usiskin et al., 1999).
1.1 Longitudinal Investigations of Neurocognitive and Psychiatric Functioning in Children
with 22q11DS
In one of the first longitudinal studies of individuals with 22q11DS, Gothelf et al. (2005)
reported significant declines in verbal IQ and expressive language scores across two time
points separated by approximately five years. Similar findings were identified in subsequent
longitudinal examinations by Gothelf and colleagues with an association between changes in
various cortical structures, verbal deterioration, and the appearance of severe
psychopathology being highlighted (Gothelf et al., 2007; Green et al., 2009). Abnormal
developmental trajectories of cortical thickness, with cortical loss during adolescence, has
been documented both cross-sectionally and longitudinally, which may affect
neurocognitive and psychiatric functioning over time (Schaer et al., 2009). Most recently,
Kates and colleagues documented a relationship between changes in brain structure and the
emergence of prodromal schizophrenia symptoms at two time points over a three year time
period (Kates, Antshel, et al., 2011; Kates, Bansal, et al., 2011). Although the developmental
trajectories of most brain structures were similar to their matched controls, volumetric
decreases in temporal lobe gray matter and verbal IQ were especially related to positive
prodromal psychotic symptoms in their preadolescent sample of children with 22q11DS.
Green et al. (2009) noted the need for ongoing prospective longitudinal studies to continue
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to examine the nature of these changes. Since most of the above studies included children
with 22q11DS that were older or included both children and adults and/or examined change
over time mainly as related to schizophrenia symptoms, little is known about the
longitudinal changes in neurocognition and other psychiatric diagnoses in early adolescence.
1.2 The Present Study
The primary purpose of the current study was to examine the longitudinal
psychoeducational, neurocognitive, and psychiatric functioning of a well characterized
group of children and young adolescents with 22q11DS. We had previously reported
children with 22q11DS as having an IQ in the borderline range, with deficits in executive
function, attention and verbal memory (Lewandowski et al., 2007; Shashi, Berry, &
Keshavan, 2009). Our first research objective in this study was to provide a more
comprehensive description of the psychoeducational, neurocognitive and psychiatric
findings of our sample at T1, and also provide the newest findings of our sample’s
performance 3.5 years later (T2). A second research question examined change over time for
the 22q11DS group in comparison to age and gender matched healthy controls across the
psychoeducational, neurocognitive, and psychiatric domains. Finally, a third research
question examined specific T1 variables as potential predictors of the emergence of targeted
psychopathology at T2, approximately 3.5 years post study entry.
2. Methods
2.1 Participants
Forty-two children with 22q11DS, ages 7.0-15.67 years (M = 10.05, SD = 2.49), were
recruited either at Duke University Medical Center (DUMC) or Wake Forest Baptist
Medical Center. All subjects with 22q11DS had a molecularly confirmed deletion of the
22q11.2 region. Twenty-nine healthy control participants were recruited by advertisement in
local pediatric practices, schools, and the research study website at DUMC. Control
participants ranged in age from 7.92 to 14.33 years (M = 10.13, SD = 1.74) and were
excluded if they had a severe neurodevelopmental disorder (e.g., Autism), or a personal or
family history (first-degree relative) of Psychosis, Bipolar Disorder, or Major Depression.
2.2 Measures
Participants were administered measures to ascertain intelligence (Wechsler Intelligence
Scale for Children-III/IV [WISC-III/IV] Verbal Comprehension, Perceptual Reasoning, Full
Scale IQ; Wechsler, 1991, 2003), academic achievement in reading, mathematics, and
spelling (Wechsler Individual Achievement Test-II/III [WIATII/III] Reading, Mathematics,
Spelling; Wechsler, 2001, 2009), and a priori designated aspects of neurocognition including
attention (Continuous Performance Test Identical Pairs d-Prime and AX d-Prime [CPT-IP/
AX]; Cornblatt, Risch, Faris, Friedman, & Erlenmeyer-Kimling, 1988), verbal memory
(California Verbal Learning Test for Children [CVLT-C] Total Score; Delis, Kramer,
Kaplan, & Ober, 1993), and the executive functions of perseveration, cognitive flexibility
(Wisconsin Card Sorting Test [WCST] Perseveration Errors; Chase-Carmichael, Ris,
Weber, & Schefft, 1999), working memory (WISC-IV Working Memory Index; Wechsler,
2003), and processing speed (WISC-IV Processing Speed Index; Wechsler, 2003). Due to
the high risk of schizophrenia in later life for children with 22q11DS, these measures were
selected based on the recommendations of the Measurement and Treatment Research to
Improve Cognition in Schizophrenia (MATRICS) task force, developed by the National
Institute of Mental Health (NIMH). This task force identified seven domains of cognitive
functioning and impairment that are central to schizophrenia, such as Speed of Processing,
Attention/Vigilance, Working Memory, Verbal Learning, (Kern, Green, Nuechterlein, &
Deng, 2004).
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Psychiatric status was assessed by the presence of psychiatric diagnoses (Computerized
Diagnostic Interview Schedule for Children, Version IV [DISC-IV]; Shaffer, Fisher, Lucas,
Dulcan, & Schwab-Stone, 2000), and social-behavioral functioning (Child Behavior
Checklist Internalizing, Externalizing, and Total Problems summary scores; Achenbach &
Ruffle, 2000; Social Skills Rating System Total Score and Behavior Problems Score;
Gresham & Elliot, 1990), as reported by parents. Prodromal symptoms of schizophrenia
were assessed using the Structured Interview for Prodromal Symptoms (SIPS; McGlashan et
al., 2001) and Global Assessment of Functioning (GAF) with the Diagnostic and Statistical
Manual of Mental Disorders GAF Scale (4th ed., text rev.; DSM-IV-TR; American
Psychiatric Association [APA], 2000), and socioeconomic status (SES) of participants’
families was ascertained using the Hollingshead Two Factor Index of Social Position Scale
(Hollingshead, 1957).
The initial neuropsychological and psychiatric evaluations were administered followed by a
subsequent evaluation (T2) approximately 3.46 years (SD = 0.93 years) later in the 22q11DS
group and 3.5 years (SD = 0.73 years) later in the control group, F (1, 67) =.37, p = .54.
Evaluations were conducted by trained psychology graduate students and post-doctoral
fellows in clinical psychology under the supervision of a licensed neuropsychologist. Those
conducting the evaluations were not blinded to the intent of the study or group membership
of the participant.
2.3 Data Analyses
Preliminary analyses examined group differences at T1 and T2 on sociodemographic
variables to determine the need to control for any of these variables in subsequent analyses
and to address the first research question. The two groups were compared across the
psychoeducational, neurocognitive, and psychiatric variables using a multivariate analysis of
variance (MANOVA), with follow-up univariate procedures to compare continuous
variables and associated partial eta square (η2p) as a metric for effect sizes. Fisher’s Exact
Test (FET) and Chi-Square procedures were used for comparison of categorical variables.
For group comparison on the neurocognitive variables, chronological age was included as a
covariate given that the CPT-IP/AX variables were entered as raw scores and needed to be
adjusted for age. To correct for error inflation due to multiple post-hoc comparisons,
individual analyses of variance (ANOVA) were examined only if the overall MANOVA
model was significant.
To address the second research question related to change over time, similar analytic
strategies were employed, with a particular focus on the group x time point interaction.
Additionally, to examine possible changes in the presence of specific psychiatric diagnoses
and symptoms, we characterized change as a categorical variable (i.e., no change, loss of a
diagnosis, gain of a diagnosis) for targeted diagnoses (i.e., Schizophrenia, ADHD, Any
Anxiety Disorder, Specific Phobia, Major Depression) and for schizophrenia symptoms (no
change, fewer, or more symptoms), and conducted Chi Square analyses to examine any
differential change in diagnosis between the groups.
Finally, to address the third research question, a series of linear regression models were
employed solely with the 22q11DS sample to identify specific predictors for symptoms of
Specific Phobia, OCD, Major Depression, ADHD, and Schizophrenia. The regression
models were constructed using preliminary correlations between the socioeconomic,
psychoeducational, neurocognitive, and psychiatric variables at T1 and the number of
symptoms for each disorder at T2. For all data analyses we used SPSS version 18.0.
Hooper et al. Page 4















3.1.1 Initial Evaluation at Time 1 (T1)—Data were collected from 71 participants at T1,
of which 42 were diagnosed with 22q11DS and 29 were healthy controls. Initial
neuropsychological results on a subset of these individuals have been previously reported
elsewhere (Lewandowski et al., 2007). All 71 participants are part of a cohort of over 160
children with 22q11DS and control subjects who are part of a longitudinal study to ascertain
the trajectory of neuropsychology in children with 22q11DS. In the current study, we report
on T1 and T2 findings for only those participants on whom we have completed a T2
assessment. A one-way analysis of variance (ANOVA) indicated no differences at T1
between the two groups on age, F (1,70) =0.02, p =.88, or gender, FET p = .48, with 43% of
the 22q11DS group and 51% of the control group being female. There was also no
significant difference in SES between the two groups, F (1,70) =2.5, p =.116 (22q11DS
M=33.21, SD =14.56; Control M =27.86, SD = 12.97). Finally, no significant differences in
ethnicity were noted between the 22q11DS and control groups, χ2 (2) =1.05, p = .591, with
92% of the 22q11DS group and 86% of the control group being Caucasian. The remaining
ethnic categories were Hispanic (22q11DS=3%, Controls=7%) and African-American
(22q11DS= 5%, Controls= 7%).
3.1.2 Follow-Up Evaluation at Time 2 (T2)—At T2, there were no significant
differences between the groups on age, F (1,70) =.190, p =.66, (22q11DS M=13.59, SD =
2.47 years; Control M=13.82, SD= 1.74 years), or SES, F (1,68) =1.12, p =.293, (22q11DS
M =31.36, SD = 14.8; Control M=27.56, SD=14.1).
3.2 Research Question 1: Group Differences at Study Entry (T1) and Follow-up (T2)
3.2.1 Psychoeducational Findings—Psychoeducational findings from T1 and T2 can
be seen in Table 1. At study entry, a MANOVA indicated significant differences between
the 22q11DS and control groups on three indices of the WISC-IV with follow-up univariate
ANOVAs showing significant differences between the two groups on all indices. On each
index, children with 22q11DS scored significantly lower than controls, with effect sizes
being large in magnitude.
A similar pattern was found for academic achievement scores, with an overall MANOVA
showing a significant group difference on the WIAT scores. Achievement effect sizes
ranged from moderate (spelling) to large (reading and mathematics).
At the T2 evaluation, the groups continued to be significantly different on the three WISC-
IV indices with follow-up univariate procedures showing differences on all the indices. As
with T1, participants with 22q11DS scored lower on all three indices than the controls, with
effect sizes remaining large in magnitude. Likewise, the 22q11DS group scored significantly
lower than controls on the achievement measures of the WIAT. Effect sizes remained the
same as at T1, ranging from moderate (spelling) to large (reading and math).
3.2.2 Neurocognitive Findings—Table 1 contains the neurocognitive means and
standard deviations for each group at T1 and T2. For T1, a multivariate analysis of
covariance (MANCOVA), controlling for chronological age, indicated a significant overall
difference between the two groups. Follow-up univariate procedures revealed significant
group differences on measures of attention, verbal memory, and executive functions. Effect
sizes for all of the findings were in the moderate to large range.
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Examination of the neurocognitive findings at T2 continued to show significant differences
between the groups. Specific group differences continued to be found on the CPT AX d-
Prime, CVLT Total, WCST Perseverative Errors, WISC-IV Working Memory, and WISC-
IV Processing Speed. Effect sizes for each of these differences continued to fall within the
large range.
3.2.3 Psychiatric Findings—Table 2 contains the psychiatric findings for each group at
T1 and T2. At T1, a MANOVA for general social-behavioral functioning revealed
significant group differences. Follow-up univariate procedures showed significant
differences between the two groups on the CBCL Total Problems and Internalizing
Problems scales, with the individuals in the 22q11DS group showing more behavior
problems than controls. Significant differences were not found on the CBCL Externalizing
Problems scale or either of the SSRS scales. Overall effect sizes on the social-behavioral
measures ranged from small (SSRS Total Social Skills and Behavior Problems scores,
CBCL Externalizing Problems) to moderate (CBCL Externalizing Problems and
Internalizing Problems) to large (CBCL Total Problems).
A second group comparison examined specific symptoms of targeted psychiatric diagnoses
as endorsed by parents on the CDISC. The MANOVA did not show a significant difference
between the two groups at T1 on the number of symptoms endorsed across the targeted
diagnoses. When the groups were compared on meeting full criteria for any of the targeted
psychiatric diagnoses at T1 as defined on the CDISC, participants in the 22q11DS group
were not significantly more likely to meet criteria, χ2(1) = 3.63, p= .057. This result,
however, just missed reaching significance, with 64.3% of the participants in the 22q11DS
group meeting criteria for a psychiatric diagnosis versus 41.3% of controls. The latter
percentage was inordinately high due to the allowance of healthy controls into the study
with a diagnosis of ADHD. This allowance also, however, created a conservative group
comparison on the presence of psychiatric disorders, thus making the group differences even
more striking. Given a more representative control sample, it is likely that there would have
been a significant difference between groups when looking at the presence of any
psychiatric diagnosis. Looking at group differences on specific diagnoses, a significant
difference did emerge when examining the presence of any anxiety disorder, χ2(1) = 14.8, p
< .001, with 45.2% of the 22q11DS group meeting criteria for an anxiety disorder versus
only 13.5% of controls. This was specifically due to the diagnosis of Specific Phobia, which
was more likely in the 22q11DS group, χ2 (1) = 13.13, p < .001. There were no significant
differences noted between the groups for the presence of ADHD, FET p= .98, since ADHD
was not a rule-out condition for the control group. At T1, none of the 22q11DS or control
subjects had a diagnosis of Psychosis or symptoms of a Schizophrenia Prodrome. The use of
psychotropic medication may have had an impact on whether an individual met criteria for a
specific psychiatric diagnosis; however, there were no overall differences between the
groups with respect to prescribed psychotropic medication use, χ2(2) = 0.04, p = .83.
Psychiatric findings at T2 (Table 2) were similar to those obtained at T1, with continued
significant differences between groups being noted. At this time point, however, children
with 22q11DS exhibited significantly more in the way of social problem behaviors as
reported on the SSRS. They were again rated as having higher overall CBCL Total Behavior
problems and Internalizing Problems. Effect sizes again ranged from small (SSRS Total
Social Skills, CBCL Externalizing Problems) to moderate (SSRS Behavior Problems, CBCL
Internalizing Problems), to large (CBCL Total Problems). As with T1, parent ratings of
overall social skills on the SSRS Total and CBCL Externalizing Problems were not
significantly different between groups.
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With respect to group differences on the number of psychiatric symptoms reported by
parents, an overall MANOVA was significant at T2, a different finding from T1. Children
with 22q11DS were rated as having higher numbers of symptoms of Specific Phobia,
Schizophrenia, OCD, ADHD, and Major Depression symptoms (Table1). Effect sizes were
small for these group differences.
At T2, children in the 22q11DS group continued to be more likely to meet criteria for any
DSM-IV-TR disorder overall, χ2(1) = 6.01, p = .01, any anxiety disorder overall, χ2(1) =
9.03, p < .01, and Specific Phobia, χ2(1) = 7.05, p < .01. No differences were found in rates
of diagnosis for any depression diagnosis, χ2(1) = 2.17, p = .14, ADHD, χ2 (1) = 2.1, p = .14
or Schizophrenia, χ2 (1) = 1.42, p = .23. When prodromal symptoms were examined, a
higher rate of Attenuated Positive Prodromal symptoms was seen in the 22q11DS group,
compared to the controls at T2, χ2(1) = 3.94, p =.047. At T1, none of the subjects in either
group had met criteria for the Attenuated Positive Prodromal Syndrome. As with T1, there
were no group differences in prescriptions for psychotropic medication, χ2− (1) = 2.4, p=.29.
3.3 Research Question 2: Changes in Psychoeducational, Neurocognitive, and Psychiatric
Functioning Over Time
To address the second research question, a series of MANOVAs were conducted to
investigate potential differences in the developmental trajectory of the psychoeducational,
neurocognitive, and psychiatric functioning of children with 22q11DS versus controls across
the two time points. Here we were most interested in examining the group x time interaction
across the variables so as to examine possible change over time on the various
psychoeducational, neurocognitive, and psychiatric variables.
3.3.1 Changes in Psychoeducational Functioning—A MANOVA indicated that
there was not a significant group x time point interaction for changes in cognition or
academic achievement (Table 1) over time.
3.3.2 Changes in Neurocognitive Functioning—Within the neurocognitive domain,
controlling for chronological age, a MANOVA indicated the presence of a trend towards a
significant group x time point interaction (Table 1). Examining the follow-up univariate
ANOVAs for the group x time point interaction revealed the groups to be significantly
different on CPT IP d Prime, with the individuals in the 22q11DS group showing slower
gains than those in the Control Group (Figure 1). There were no other group differences
noted with respect to changes in neurocognitive functioning over time.
3.3.3 Changes in Psychiatric Functioning—For the general social-behavioral
measures, the MANOVA produced a non-significant group x time point interaction (Table
2) and thus the individual ANOVAs were not examined. We then examined whether
subjects in each group had a change in the number of total psychiatric symptoms from T1 to
T2 (for Schizophrenia, OCD, Major Depression, Specific Phobia and ADHD) and found a
significant group difference, with more children with 22q11DS exhibiting an increase in
symptoms in each over time, relative to the control group, t (53) =2.05, p < .05.
When individual psychiatric diagnoses were examined from T1 to T2, there were no
significant changes noted for either group on any anxiety disorders, χ2(2) = 5.15, p = .07;
Specific Phobia, χ2(2) = 4.55, p = .10; Major Depression, χ2(1) = 1.42, p = .23; ADHD,
χ2(2) = 2.42, p = .29; or Schizophrenia χ2(2)= 2.7, p=.10. Qualitatively, four subjects in the
study had converted to Schizophrenia/Psychotic illness from T1 to T2. One diagnosed at the
T2 assessment and the others diagnosed in the interim. Three of the four subjects were age
16 at the time of a diagnosis of a Psychotic Disorder and the fourth was 18 years of age.
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Three had a diagnosis of Schizophrenia and the fourth was a Psychotic Disorder, NOS. The
three that had been diagnosed in the interim were all on antipsychotic medications at the
time of T2 assessment and were in remission. We also examined change in the number of
schizophrenia symptoms on the CDISC from T1 to T2 and found a significantly increased
symptom count in children with 22q11DS over time, compared to control subjects, t (43)=
2.0, p<.05.
We examined change in GAF scores from T1 to T2 in the 22q11DS versus control group
and found that the control group made significantly more improvement in their GAF score
over time compared to the 22q11DS group, t (55) = −2.32, p < .05, indicating poorer overall
function with time in the 22q11DS group.
3.4 Research Question 3: Predictors of Psychopathology
To examine what specific sociodemographic, psychoeducational, neurocognitive, or
psychiatric variables at T1 might be predictive of psychopathology at T2 in the 22q11DS
group, we conducted preliminary correlations to identify specific variables for inclusion in a
series of linear regressions. Variables that were significantly correlated with the number of
symptoms for each disorder were included in each respective model. None of the variables
were significantly correlated with Specific Phobia symptoms; consequently, a linear
regression was not conducted for these symptoms. The results from the linear regression
analyses can be seen in Table 3.
For schizophrenia symptoms, there were six different variables that were significantly
correlated: Full Scale IQ, r (37) = −.44, p <.01, Processing Speed, r (36) = −.35, p<.05,
Working Memory, r (35) = −.40, p <.05, CBCL Total Problems, r (35) =.42, p <.05, CBCL
Externalizing Problems r (35) =.37, p <.05, and SSRS Problem Behaviors, r (35) =.36, p <.
05. When these variables were entered into the linear regression, lower Full Scale IQ at T1
was the only significant predictor of increased schizophrenia at T2 (Table 3).
For ADHD symptoms, there were three variables that were significantly correlated: CBCL
Externalizing Problems, r (35) = .48, p <.01, CBCL Total Problems, r (35) = .53, p=.001,
and SSRS Problem Behaviors, r (35) = .55, p = .001. The linear regression containing these
variables as predictors found that only higher CBCL Externalizing Problems was predictive
of higher ADHD symptoms (Table 3)
For OCD symptoms, there were five variables that were correlated. These included gender,
with females having more OCD symptoms, r (38) = .38, p <.05, CBCL Total Problems, r
(35) =.40, p <.05, CBCL Externalizing Problems, r (35) =.42, p <.05, SSRS Total, r (35) =−.
43, p <.05, and SSRS Problem Behaviors, r (35) =.57, p <.001. When the individual
predictors were examined, female gender, higher CBCL Total Problem Behaviors and
higher SSRS Problem Behaviors at T1 were significant predictors of higher OCD symptoms
at T2.
Finally, for Major Depression symptoms, there were six variables that were significantly
correlated: age, r (38) =.35, p <.05, Full Scale IQ, r (37) =−.38, p <.05, Processing Speed, r
(36) = −.49, p <.01), CBCL Externalizing Problems, r (35) =.45, p <.01, CBCL Total
Problems, r (35) =.50, p <.01, and SSRS Problem Behaviors, r (35) =.41, p <.05. Among the
individual variables, Problem Social Behaviors was a significant predictor of Major
Depression symptoms at T2. Increasing age also showed a trend to being a significant
predictor (p=.05).
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The primary objective of this study was to examine the longitudinal psychoeducational,
neurocognitive and psychiatric outcomes in children and adolescents with 22q11DS at T1
and T2, with a specific focus on change over time. In addition, we were interested in
capturing predictors of emergent psychopathology within our 22q11DS sample. This study
is one of the largest, and the first to present a comprehensive longitudinal multifaceted
assessment of cognition, behavior, and psychiatric findings over time in younger children
and adolescents with 22q11DS, unlike previous studies that have largely focused on findings
related to the schizophrenia risk. Our findings revealed the 22q11DS group to be
significantly lower functioning than the controls in intellectual functioning, academic
achievement, attention, verbal memory, cognitive flexibility, working memory, and
processing speed at both T1 and T2. Children with 22q11DS also showed significantly more
social-behavioral difficulties, psychiatric symptoms, and psychiatric disorders at both time
points. These findings are similar to the available literature (Baker & Skuse, 2005; De
Smedt et al., 2007; Jacobson et al., 2010; Lewandowski et al., 2007; Murphy et al., 1999;
Papolos et al., 1996; Pulver et al., 1994; Swillen et al., 1997; Woodin et al., 2001; Young et
al., 2011) and we note that they persist over time. Thus, professionals working with this
population need to be mindful that the psychoeducational, neurocognitive, social-behavioral
and psychiatric difficulties do not improve over time.
The intellectual, academic achievement, and psychiatric outcomes targeted remained
relatively stable over the interval studied. While other investigative teams have documented
declines in overall intellectual functioning, verbal IQ, language abilities, and psychiatric
status, such decline in cognition occurred in conjunction with the emergence of psychotic
symptoms (Gothelf et al., 2007; Green et al., 2009; Kates, Antshel, et al., 2011). The lack of
such deterioration in these specific functions in our sample may be related to the relatively
younger age of our sample, as most of the children at T2 in our study have not yet entered
the age range for the highest risk of major psychiatric illnesses (mean age in our study at T2
was 13.59 years, SD = 2.47), and only a small number having converted to psychosis. In
addition, our shorter follow-up time point of 3.5 years versus 5.0 years (Gothelf et al., 2007)
may be a factor in not detecting significant changes in overall cognition and
psychopathology. However, the presence of a time point in between preadolescent and late
adolescence period, as provided in our study, should allow a more robust estimation of the
trajectory of neuropsychological changes during the early adolescent period. We also
obtained a relatively healthier cohort than in other studies. The majority of our cohort had
been identified through a genetics clinic, wherein all children with 22q11DS are seen, rather
than a specialty clinic such as a child psychiatry, neurodevelopmental, or cardiology clinic,
where a biased sample could be available. , Due to this, our findings of stability in early
adolescence may be more reflective of the state in a general community sample of children
of 22q11DS. Finally, the lack of deterioration in our sample could be secondary to
medication and other therapeutic and educational interventions being provided to the
children in our sample. However, we have shown in prior studies that the children in our
sample are not receiving all necessary treatments (Young et al., 2011), which lessens the
validity of this argument.
Despite these differences, when we examined the number of total psychiatric symptoms and
schizophrenia symptoms from T1 to T2 within the 22q11DS group, there was a significant
increase, as well as an increase in the Attenuated Prodromal Syndrome in the 22q11 group,
relative to controls, indicating that with time we could expect to see increasing number of
psychoses as well. We also demonstrated that global functioning declines over time in
children with 22q11DS, relative to controls. Furthermore, the 22q11DS group did show a
significant and differential slowing of growth in their attention over time, suggesting a new
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finding in neurocognitive change in children with 22q11DS. These deficits undoubtedly will
contribute to neurocognitive inefficiencies, and could be the precursors to later learning,
adaptive, and psychiatric difficulties with advancing age and increased environmental
challenges. These findings lead us to infer that during the early teen years, children with
22q11DS continue to experience a steady increase in psychiatric symptoms, despite no
increases in categorical psychiatric diagnoses, as well as subtle changes in neurocognition
and overall functioning. Vigilance with a goal of early detection and early intervention for
psychopathology may be able to mitigate the progression of these concerning symptoms and
signs, as these children move into the age of highest risk of major mental illnesses. Ours is
the first study to highlight these early, yet important indicators.
Finally, consistent with earlier longitudinal studies (Johnstone, Ebmeier, Miller, Owens, &
Lawrie, 2005; Kim-Cohen et al., 2003), we were able to identify specific predictors of later
psychopathology in our sample. For schizophrenia symptoms, lower Full Scale IQ at T1 was
predictive of a larger number of schizophrenia symptoms at T2. A significant linear
regression for Major Depression symptoms at T2 was observed, with problem social
behaviors as a significant predictor and increasing age showing a trend. For Specific Phobia,
none of our sociodemographic, neurocognitive, or social-behavioral variables at T1 were
correlated with the number of symptoms at T2. For ADHD, CBCL Externalizing Problems
was significantly predictive, a measure that typically is used to diagnose ADHD; and for
OCD, female gender and having more behavior problems were predictive of symptoms at
T2. Given the higher rate of psychopathology in our 22q11DS group as compared to healthy
controls, we expect to see these variables surface as predictors as our sample ages into later
adolescence and young adulthood (Johnstone et al., 2005; Kim-Cohen et al., 2003). It will be
important for these predictive models to receive replication with other 22q11DS samples.
Although this study is one of the largest longitudinal studies examining neurodevelopmental
and neuropsychiatric outcomes in children with 22q11DS, there are a few limitations. First,
our sample size is small, and this may have contributed to our lack of findings related to
change in categorical diagnoses over time as well as identifying specific predictors of
emergent psychopathology. A second limitation is that we utilized parent ratings to
determine the presence of social-behavioral difficulties, psychiatric symptoms, and specific
psychiatric diagnoses, rather than interviewing the children. Although some may see our
relatively shorter time between assessments as a limitation, we believe it a strength,
providing a window into the trajectory of neurodevelopmental changes in early adolescence.
It is also unclear how specific medications or other treatments may have affected the
developmental trajectories of this sample. Although we did not see major changes over time,
the impact of specific interventions may have had some effect on attenuating any early
potential decline in function. Finally, the evaluators conducting the assessments in this study
were not blinded to either the intent of the study or the diagnoses of the children being
evaluated. This may have had an impact on more subjective ratings such as the GAF, which
results showed were significantly different between healthy controls and the 22q11DS
group.
This study provides important findings on the functioning of children and adolescents with
22q11DS, and serves to complement the few published longitudinal investigations. Our
results showed a lower level of functioning at both time points accompanied by a heightened
degree of psychiatric impairment. Over time, there are subclinical declines in cognition and
increases in schizophrenia symptoms and prodromal signs, but in general, the presence of
psychopathology appears to be relatively stable in the early years of adolescence. It will be
critical for future studies to continue to examine the neuropsychiatric outcomes of children
with 22q11DS, and for clinicians to engage in vigilant neurodevelopmental surveillance in
later adolescence.
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Children with 22q11DS and controls underwent two neurocognitive and psychiatric
evaluations 3.5 years apart.
Significant cognitive deficits and higher incidence of psychiatric manifestations seen in
22q11DS children relative to controls at both T1 and T2.
Slowed growth in attention, increased psychiatric symptoms and prodromal signs, and
decreased GAF over time noted in 22q11DS children.
T1 predictors of psychopathology at T2 included full-scale IQ and social-behavioral
problems.
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Scatterplot of Sustained Attention Scores at T1 and T2 in the 22q11DS group, relative to the
Control group, demonstrating that there is a lack of an increase in CPT scores with age in
the 22q11DS group, compared to the Control group
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Table 1


































































































































































CPT-AX – Continuous Performance Test-AX Version; CPT-IP = Continuous Performance Test-Identical Pairs Version; CVLT = California Verbal
Learning Test; WCST = Wisconsin Card Sorting Test; WISC-IV = Wechsler Intelligence Scale for Children, Fourth Edition. The MANCOVA for
the neurocognitive measures used age as a covariate, since the CPT scores measures were entered as raw scores
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Table 2
Group Comparisons at Time 1, Time 2, and Group x Time Interactions for Psychiatric Functioning.
Psychiatric
Measures






































































































































































CDISC = Computerized Diagnostic Interview Schedule for Children;
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ADHD = Attention Deficit-Hyperactivity Disorde
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